On Chemball

My Chemball

As Supplier

My RFQ Manage Products

As Buyer

My RFQ Post RFQ

My Account

+86-571-8627 3270

Junye Pharmaceutical Co., Ltd

26 YRS

Zhejiang, China

CNY 97.5 Million

500-1000 people

Main Products: Drospirenone / Norethisterone / Norethindrone Acetate / Norethisterone Enanthate / Progesterone / Ulipristal Acetate / Dexamethasone / Dexamethasone Sodium Phosphate / Abiraterone / Finasteride / Hydrocortisone Acetate / Hydrocortisone / Deflazacort / β-Estradiol / Oestradiol 17-Heptanoate / Estradiol Valerate / Medroxyprogesterone Acetate / Hydroxyprogesterone Caproate / 17α-Ethynylestradiol / Estriol / Prednisolone / Prednisolone Acetate / Trilostane / Altrenogest / Eplerenone / Tibolone / Flumethasone / Fulvestrant / Oxandrolone

Zhejiang, China

Contact Supplier

Home Company Profile Contact Us Post Buying Request

Eplerenone / CAS 107724-20-9

OVERVIEW

Packaging

25 KG/Fibre Drum

Lead Time

14-30 days

REQUEST A QUOTATION

Submit

Get Free Samples

Less than 1KG required

DESCRIPTION

Eplerenone

CAS:107724-20-9

Molecular formula：C24H30O6

Molecular weight：312.44600

Appearance:White to grayish white crystalline powder

Synopsis：Eplerenone, a new selective aldosterone receptor antagonist, was approved by the State Food and Drug Administration for clinical application in 2002. It has a stronger antagonistic effect on aldosterone than spironolactone, and has a very low affinity for androgen and progesterone receptors. It has a definite curative effect on the treatment of high blood pressure, heart failure and myocardial infarction with less adverse reactions and good tolerance, It is a good substitute for spironolactone. For severe hypertension which can not be controlled by combination of antihypertensive drugs, eplerenone can significantly reduce blood pressure, especially systolic blood pressure. It is closely related to angiotensin converting enzyme inhibitor (ACEI) and β Receptor blockers can improve the quality of life and reduce mortality in patients with severe heart failure and myocardial infarction.

Structural formula:

Typical Properties

Eplerenone, a new selective aldosterone receptor antagonist, was approved by the State Food and Drug Administration for clinical application in 2002. It has a stronger antagonistic effect on aldosterone than spironolactone, and has a very low affinity for androgen and progesterone receptors. It has a definite curative effect on the treatment of high blood pressure, heart failure and myocardial infarction with less adverse reactions and good tolerance, It is a good substitute for spironolactone. For severe hypertension which can not be controlled by combination of antihypertensive drugs, eplerenone can significantly reduce blood pressure, especially systolic blood pressure. It is closely related to angiotensin converting enzyme inhibitor (ACEI) and β Receptor blockers can improve the quality of life and reduce mortality in patients with severe heart failure and myocardial infarction.

CAS No.

107724-20-9

Formula

C24H30O6

Molecular Mass

414.49100

Exact Mass

414.20400

PSA

82.20000

Logp

3.12450

IUPAC

methyl (1R,2S,9R,10R,11S,14R,15S,17R)-2,15-dimethyl-5,5'-dioxospiro[18-oxapentacyclo[8.8.0.01,17.02,7.011,15]octadec-6-ene-14,2'-oxolane]-9-carboxylate

SMILES

CC12CCC(=O)C=C1CC(C3C24C(O4)CC5(C3CCC56CCC(=O)O6)C)C(=O)OC

Matter Classification

organic

GET SAMPLE